Company: DRTSW
Filing Date: 2025-06-17
Form Type: 6-K
Source: 0001213900-25-055181
Chunk: 0

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-06-17
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-41316

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

On June 17, 2025, Alpha Tau Medical Ltd. (the
“Company”) held its Annual General Meeting of Shareholders (the “Meeting”) at the Company’s
headquarters at 5 Kiryat Hamada St., Jerusalem 9777605, Israel.

At the Meeting, the Company’s shareholders approved the following
proposals:

| (1) | To re-elect each of Alan Adler and S. Morry Blumenfeld, and                                                                                
 to elect Nadav Kidron, as Class I directors, to hold office until the close of the Company’s Annual General Meeting of Shareholders        
 in 2028, and until their respective successors are duly elected and qualified, or until their respective offices are vacated in accordance 
 with the Company’s Amended and Restated Articles of Association or the Israeli Companies Law, 5759-1999 (the “Companies                    
 Law”);                                                                                                                                     |

| (2) | to approve the issuance of warrants to purchase 2,390,000                                                                               
 ordinary shares of the Company, no par value (“Shares”) each with an exercise price of $3.90 per share, and warrants                    
 to purchase 847,000 Shares each with an exercise price of $3.474 per share, pursuant to the strategic services agreement by and between 
 the Company and Oramed Ltd. dated April 24, 2025;                                                                                       |

| (3) | to approve the re-appointment of Kost, Forer, Gabbay &                                                                             
 Kasier